or Try an Advanced Search...

    Alnylam Pharmaceuticals Stocks List

    Symbol Grade Name % Change
    PRQR A ProQR Therapeutics B.V. 6.57
    VIR B Vir Biotechnology, Inc. 23.63
    ALNY C Alnylam Pharmaceuticals, Inc. 2.75
    RGLS F Regulus Therapeutics Inc. 2.05
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Biopharmaceutical Biotechnology Oligonucleotide Regulus Therapeutics Therapeutic Gene Modulation Acute Intermittent Porphyria Alpha 1 Antitrypsin Deficiency Amyloid Amyloidosis Antitrypsin Deficiency Atherosclerosis Beta Thalassemia Blastoma Carcinoma Cholesterol Clinical Development Coronavirus Cystic Fibrosis Deficiency Dimm

    Related ETFs - A few ETFs which own one or more of the above listed Alnylam Pharmaceuticals stocks.

    Symbol Grade Name Weight
    GNOM F Global X Genomics & Biotechnology ETF 8.77
    PBE C PowerShares Dynamic Biotech & Genome 5.57
    HRTS D Tema Cardiovascular and Metabolic ETF 5.47
    MNTL D Tema Neuroscience and Mental Health ETF 4.96
    MEDX D Horizon Kinetics Medical ETF 4.6
    View all Alnylam Pharmaceuticals ETFs...
    Compare ETFs
    Compare HRTS to MEDX Compare HRTS to MNTL Compare PBE to HRTS

        Alnylam Pharmaceuticals Stocks Recent News

        Date Stock Title
        Nov 1 VIR Vir Biotechnology Inc (VIR) Q3 2024 Earnings Call Highlights: Strategic Restructuring and ...
        Nov 1 VIR Vir Biotechnology Q3 2024 Earnings Preview
        Nov 1 VIR Vir Biotechnology (NASDAQ:VIR) shareholders have endured a 76% loss from investing in the stock three years ago
        Nov 1 ALNY Alnylam Q3 Loss In Line With Estimates, Revenues Miss, Stock Down
        Nov 1 ALNY Alnylam Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
        Nov 1 ALNY Alnylam Pharmaceuticals Inc (ALNY) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...
        Nov 1 ALNY Decoding Alnylam Pharmaceuticals Inc (ALNY): A Strategic SWOT Insight
        Nov 1 ALNY Q3 2024 Alnylam Pharmaceuticals Inc Earnings Call
        Nov 1 VIR U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain Partners
        Nov 1 VIR Vir Biotechnology, Inc. (VIR) Q3 2024 Earnings Call Transcript
        Oct 31 VIR Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Lags Revenue Estimates
        Oct 31 VIR Vir Biotechnology GAAP EPS of -$1.56 misses by $0.60, revenue of $2.38M misses by $3.13M
        Oct 31 VIR Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
        Oct 31 ALNY Alnylam Pharmaceuticals, Inc. 2024 Q3 - Results - Earnings Call Presentation
        Oct 31 ALNY Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2024 Earnings Call Transcript
        Oct 31 ALNY Alnylam (ALNY) Reports Q3 Earnings: What Key Metrics Have to Say
        Oct 31 ALNY Alnylam Pharmaceuticals (ALNY) Reports Q3 Loss, Lags Revenue Estimates
        Oct 31 ALNY Alnylam: Q3 Earnings Snapshot
        Oct 31 ALNY Alnylam Pharmaceuticals Non-GAAP EPS of -$0.50 misses by $0.11, revenue of $500.92M misses by $26.1M
        Oct 31 ALNY Alnylam Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Period Activity
        Related Industries: Biotechnology
        Related Stock Lists: Biopharmaceutical Biotechnology Oligonucleotide Regulus Therapeutics Therapeutic Gene Modulation Acute Intermittent Porphyria Alpha 1 Antitrypsin Deficiency Amyloid Amyloidosis Antitrypsin Deficiency Atherosclerosis Beta Thalassemia Blastoma Carcinoma Cholesterol Clinical Development Coronavirus Cystic Fibrosis Deficiency Dimm
        Alnylam Pharmaceuticals

        Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

        More about Alnylam Pharmaceuticals
        Browse All Tags